Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia

We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 years were all registered. Thirty-three of 68 patients (49%) achieved remission. Median disease-free survival was 10 months and overall survival was nine months. Performance status after chemotherapy in patients who achieved remission was generally favorable. The present study demonstrates that CAG therapy is efficacious and well tolerated in the majority of elderly patients.